ASP6981 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 22, 2018 → May 30, 2018
NCT ID
NCT03356639About ASP6981 + Placebo
ASP6981 + Placebo is a phase 1 stage product being developed by Astellas Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03356639. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03356639 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia